Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years.

Alzheimers Dement (N Y) · 2015 · PMC5975050 · PMID 29854931

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

did not reach statistical significanceP = .06so close (0.05 < p ≤ 0.1)

This single primary outcome did not reach statistical significance in the smaller mild-only subgroup in EXPEDITION2 ( P = .06) [7] .

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.